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Abstract
Background: European legislation prohibits direct-to-consumer advertising of prescription medicines, but allows
drug manufacturers to provide information to the public on health and diseases. Our aim was to measure the
frequency of disease awareness campaigns in Latvian media and assess their compliance with international and
European standards.
Methods: Materials on health/disease and treatments were collected between April and September 2015 from 12
newspapers and magazines and six online portals. Disease awareness campaigns were assessed using a previously
developed instrument based on the WHO Ethical Criteria for Medicinal Drug promotion and European standards (EU
law and pharmaceutical industry self-regulatory guidelines). Collected materials were used to examine the information
provided on medical conditions and their diagnosis and treatment. The inter-rater reliability was calculated.
Results: We collected 263 materials from print (n = 149) and online media (n = 114); 94 were news items and 169 were
disease-awareness advertisements. Cancer, cardiovascular problems, allergies and respiratory diseases were common
topics. Of the 157 campaigns assessed, non-compliance was identified in 149 cases (inter-rater reliability 90%), mainly
due to misleading or incomplete information, lack of balance and the absence of a listed author/sponsor. Six disease
awareness campaigns directly mentioned a pharmaceutical product by brand name and other four included the logo
or name of a manufacturer, referred to a condition and indirectly mentioned a treatment, all in contravention with
European law.
Conclusions: The compliance of disease awareness campaigns in Latvian media with international and European
standards is low. This raises concerns about the nature of information being conveyed. Through lack of balance,
missing sponsorship information, and misleading or incomplete information, these campaigns could contribute to
inaccurate self-diagnosis and generate demand among those who might not need medical treatment.
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Background
In countries where direct to consumer (DTC) advertising
of prescription medicines is banned, companies are testing
the limits of regulatory systems with disease oriented ad-
vertising, public relations campaigns and unbranded ad-
vertising to the public [1–3]. The approach behind such
activities is that mass media expands the patients’ disease
and/or drug awareness and motivates them to visit physi-
cians for previously untreated conditions [4]. Promotional
campaigns aimed at physicians are often run concomi-
tantly so that practitioners have a specific product in mind
when patients ask about new treatments [5].
Proponents of direct-to-consumer communication high-
light the need to empower the patient by facilitating access
to information which increases knowledge about medi-
cines, diseases and therapeutics [2]. A greater involvement
of patients in their treatment could be regarded as con-
tributing to safer consumer choices and improved patient
autonomy [6]. Similarly, greater awareness about diseases
could lead to better detection, diagnosis and treatment
[7]. On the other hand, users might not always be able to
judge the information conveyed [2] and campaigns could
encourage healthy people to seek unnecessary tests or
medication [8]. Campaigns at the time of launch of a new
drug could have especially negative implications given the
limited evidence available about a drug’s risk profile.
Moreover, if the information provided is portrayed as a
community service, the public might remain unaware of
its commercial intent [5].
One key concern is that campaigns could contribute
to overdiagnosis which occurs when people are labelled
with or treated for a disease that would never cause
them harm, leading to the overuse of further tests and
treatments [9]. Overdiagnosis happens in a range of
common conditions and appears to be increasing [10].
The pharmaceutical and medical device industries,
which aim to maximize health but also has a conflicting
interest in expanding product sales, are one of the rec-
ognized drivers of overdiagnosis [1, 9].
Disease awareness or condition-oriented campaigns
can be effective tools in familiarizing consumers with a
disease and a specific pharmaceutical intervention and
raise therefore ethical and public health questions simi-
lar to those of direct-to-consumer drug promotion [11].
Bearing this in mind, it is pertinent to explore whether
the information conveyed in such campaigns is meeting
current legal and ethical standards and to distinguish le-
gitimate health information from promotional activities.
Drug manufacturers are legally prohibited from communi-
cating directly with consumers about their prescription-only
products, except in New Zealand and in the United States of
America [12]. European Union (EU) legislation prohibits
direct-to-consumer advertising of prescription medicines as
a public health protection measure [13]. However,
campaigns to the public about diseases and health from drug
manufacturers are allowed, provided there are no direct or
indirect references to specific prescription-only medicines
[14]. Each member state is then responsible for transposing
and implementing the directive. In Latvia, legal provisions
on medicines’ advertising define pharmaceutical promotion
as “any form of notification, activity, and measure if the pur-
pose thereof is to promote the prescription, distribution, or
use of medicinal products” [15] but there is no specific guid-
ance about the provision of health and treatment informa-
tion. The same applies to the national voluntary code of
conduct published by pharmaceutical manufacturers’ associ-
ations on which national self-regulatory mechanisms are
based [16].
While the literature on disease awareness campaigns is
relatively scarce and comes from industrialized coun-
tries, there is some evidence that such activities increase
awareness of the advertised conditions, as well as rates
of consultations and prescriptions of the sponsored
product [17–19]. Research in Australia and the
Netherlands also suggest that exposure to this type of
campaigns is relatively common [20, 21]. In a previous
study, we developed an instrument to assess the compli-
ance of printed disease awareness campaigns in the
Netherlands with international and Dutch regulations
[21]. Although this was a small pilot study over a short
study period, it identified an alarming lack of compliance
of disease awareness campaigns in Dutch printed media
with the WHO Ethical criteria for medicinal drug pro-
motion [22] and with national pharmaceutical industry
self-regulatory guidelines [23], as well as some evidence
of likely contraventions of EU legislation.
We aim to use that same instrument over a longer
period in another EU member state – Latvia - where sig-
nificantly less resources are devoted to health and
out-of-pocket payments for health are among the high-
est when compared to other countries in the Organisa-
tion for Economic Cooperation and Development [24].
This study measures the frequency of health and treatment
information in printed and online media in Latvia and
compares the information provided in news items and dis-
ease awareness campaigns. It also assesses the compliance
of disease awareness campaigns with the WHO Ethical Cri-
teria and European standards (namely European Union law
and the pharmaceutical industry self-regulatory guidelines
for Information on Prescription-only medicines). This is
the first study to examine disease awareness campaigns in
the Baltic Region.
Methods
Selection and coding of materials
Data collection took place from April to September
2015. We selected the three top print and online media
targeting a varied audience in Latvia, available in either
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Latvian or Russian language, based on high circulation
and subscription numbers from publicly available reports
[25–27]. These included: three daily and three weekly
newspapers; three monthly and three health magazines;
three news and three health portals (see Additional file 1:
Table S1). All were accessed at public libraries and avail-
able either in Latvian or Russian. In Latvia, 37.2% of the
population are Russian-speaking and media are available
in both languages [28].
From all the items covering health topics identified in
the various media, we selected materials which men-
tioned conditions or symptoms or manufacturers and
provided treatment suggestions (either directly or indir-
ectly). The full inclusion criteria followed the method-
ology of a previous study [21] and were based on an
interpretation of legal provisions [14], which prohibit
direct and/or indirect reference to a pharmaceutical
product. From all the items covering health topics iden-
tified in the various media, we selected materials which
mentioned conditions or symptoms or manufacturers
and provided treatment suggestions (either directly or
indirectly). Materials on issues governed by different reg-
ulations such as nutraceuticals, homeopathic products,
over-the-counter medication and vaccines were ex-
cluded. Prior to data collection, a training session was
conducted on application of inclusion criteria and the
instrument, with methods piloted during late 2014 and
early 2015. Three researchers (EP, SM, LA) then selected
materials published between April and September 2015,
with duplicate independent screening of all included
media and any disagreements resolved by consensus.
Classification of materials: Identifying disease awareness
campaigns
We separated the collected materials into two groups:
 Group I were news items with listed authors or
attributed to a news desk. These were not assessed
using the tool as reports by the press to the public
are not subject to regulations or guidelines on
pharmaceutical promotion.
 Group II were disease awareness campaigns without
a listed author. These were scored using the
instrument described below.
We extracted general and key content characteristics
for both Group I and Group II materials on the follow-
ing factors:
 publication type: subscription status (paid or free);
language; frequency;
 author (yes/no);
 content: non-drug options mentioned; physician re-
ferral; reference to clinical expert or spokesperson;
referral to patient organization or support group;
one or more brand-name drugs recommended;
availability of new treatment noted; referral to a
website; company’s name or logo listed; sponsored
by a clinic or hospital.
Assessing compliance of disease awareness with
guidelines
We applied an instrument developed in a previous study
[21] and based on seven relevant criteria from the WHO
Ethical Criteria for Medicinal Drug Promotion [22] and
Dutch pharmaceutical industry self-regulatory guidelines
[23]. These include use of: promotional information;
misleading or incomplete information; fear; inadequate
language; lack of balance; testimonials; and absence of
source/author. Dutch and Latvian self-regulatory codes
on pharmaceutical promotion are subject to EU regula-
tions [14] and are generally similar in approach as they
are both based on the self-regulatory codes issued by the
European Federation of Pharmaceutical Industries and
Associations (EFPIA) [29]. Additional file 2: Table S2 de-
scribes the overlap between relevant provisions in inter-
national guidelines and the instrument’s domains.
Websites that were mentioned in disease awareness
campaigns were also assessed using the instrument and
the results of that assessment are presented separately.
Three authors (EP, LA, ISK) independently pilot tested
the instrument on a sample of materials (n = 20). Mate-
rials were duplicate coded and differences in scoring re-
solved through consensus.
Statistics
Descriptive statistics are presented and risk ratios (RR) were
calculated comparing frequencies of information provision
in news items (Group I) and disease awareness campaigns
(Group II). Inter-rater reliability was measured using the
intraclass correlation coefficient two-way random effects
model [30]. We used chi-square to test for differences by
language (reported jointly if similar). Frequency of
non-compliance per key criteria was compared between the
Latvian campaigns and those of a previous Dutch study
[21]. Data analysis was conducted using SPSS version 24.
Results
Assessing disease-awareness frequency in media
A total of 263 materials were collected, 94 (35.7%) of
which were news items (Group I) and 169 (64.2%) were
disease awareness campaigns to be scored by the instru-
ment (Group II) (see Fig. 1). This means that on average,
ten materials covering disease and treatment topics were
published in print or online media every week, 6 of
which were disease awareness campaigns. We identified
12 duplicate disease awareness campaigns within Group
II, which were excluded for all other analyses. Three
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media sources (n = 3) contained no materials on health
and treatment. Results are presented jointly for Latvian
and Russian media as information frequency did not dif-
fer significantly by language. The most common topics
in news items were dermatological problems (12.8%),
cancer (11.7%), cardiovascular diseases (9.6%), pain
(9.6%), and gastrointestinal disorders (5.3%). Within dis-
ease awareness campaigns, the most frequent themes
were cardiovascular diseases (10.7%), dermatological
problems (8.3%), cancer (7.7%), urological problems
(7.7%), and pain (7.1%).
As is described in Table 1, news items included quotes
from key opinion leaders more often, and mentioned the
availability of a new treatment, whereas disease aware-
ness campaigns were more likely to refer viewers to a
website (RR = 4.04, 95%CI 1.46;11.19) or a pharmaceut-
ical company (RR = 7.78, 95%CI 1,03;58.55). These
disease-awareness campaigns were also often sponsored
by a hospital or clinic (RR = 3.29, 95% CI 1.17;9.26).
Nearly all the materials recommended seeing a phys-
ician. Quoted key opinion leaders were most frequently
general practitioners and leading specialist physicians
from academic hospitals, such as cardiologists and gas-
troenterologists. Non-drug or lifestyle interventions were
mentioned over half the time, although this occurred
more often in news items than in disease awareness
campaigns. The type of lifestyle interventions mentioned
most frequently were exercise (e.g. for depression, vari-
cose veins, pain, urological problems); and psychother-
apy (e.g. in cases of depression, compulsive eating,
vegetative dystonia).
Compliance of the disease awareness campaigns with
guidelines
Of the 157 diseases awareness campaigns assessed, 149
(94.9%) were non-compliant. Inter-rater agreement for
independent coding of judgments of compliance with
guidelines was high: 0.906 [95% CI 0.877; 0.929].
Non-compliance was most often due to the absence of
author or source (n = 131, 78%), use of misleading or in-
complete information (n = 61, 36%), or lack of balance
(n = 58, 35%). In total, 29.9% (n = 50) of campaigns were
non-compliant with two criteria and 19.1% (n = 32) with
three criteria.
Table 2 provides some examples of non-compliance
per key criteria and campaign topic.
Figure 2 provides an overview of compliance levels per
key criteria, and compares results with those obtained in
the Dutch study [21]. The Latvian campaigns seemed
overall more compliant with standards than the Dutch
but were more likely to not to mention an author/spon-
sor, contain misleading or incomplete information or in-
adequate language.
Twenty-three of the 157 campaigns (14.6%) listed dedi-
cated websites, 20 (86,9%) of which were also non-compli-
ant with guidelines. Eight of these websites were
sponsored by a pharmaceutical company. Ten disease-
awareness campaigns (6.4%) were likely in contravention
of European law: four included the logo or name of a
pharmaceutical company and both referred to a condition
and mentioned a treatment indirectly; six mentioned a
medicine by its brand name.
Discussion
Our study confirms that there is a strong focus on health
and treatment information in Latvian media with more
than ten items being published every week covering vari-
ous topics, including both health-related news items and
disease-awareness campaigns. An average of six disease-
awareness campaigns were published per week, which is a
higher frequency than that reported in similar studies in
the Netherlands and in Australia [20, 21].
Fig. 1 Materials collected and their allocation per type of media and sponsor, when applicable
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In this sample, the overwhelming majority of Latvian
disease-awareness campaigns (94.9%) did not comply
with the WHO Ethical Criteria for Medicinal Drug Pro-
motion [22] nor with self-regulatory standards [23]. The
overall compliance results seem somewhat more positive
than those obtained in the Dutch study [21], but 58.6%
of the campaigns included in our Latvian sample failed
to comply with two or more of these key criteria.
According to the WHO ‘promotion’ includes all infor-
mational and persuasive activities of manufacturers and
distributors, that affect the prescription, supply, purchase
and/or use of medicinal drugs" [22]. Although disease
awareness campaigns can contain information which
might be of potential value to the public, they also have
many characteristics that would make them promotional
and are, in some cases, clearly designed to support treat-
ment with a sponsor’s product as part of a marketing
campaign. They are not subject to the same type of
regulatory oversight in Latvia as other types of pharma-
ceutical promotion. Generally, if the product name is
not mentioned, these are not considered to be pharma-
ceutical advertising, even if the sponsor has a product
on the market to treat the condition that is under
discussion.
In 78% of the cases we were unable to identify the
author or sponsor of the campaigns. This means that
the target audience might remain unaware of the in-
tent of the information conveyed [5] and of its poten-
tial commercial source. Ebeling describes ‘condition
branding’ as an essential component of direct-to-con-
sumer marketing of pharmaceuticals in the United
States, with the definition of symptoms associated
with a specific treatment being a key focus of activ-
ities aiming to create a market for newly developed
products [31]. In a randomized trial of a fictitious
advertising campaign, consumers tended to perceive
disease awareness campaigns more positively than
branded advertisements, and stated their intent to
seek information and treatment more often after
viewing disease awareness campaigns [32].
Some of the conditions mentioned in non-compliant
campaigns in our sample have been highlighted in the
medical literature as subject to overdiagnosis: female
sexual dysfunction, overactive bladder, erectile dysfunc-
tion, nail fungus, seasonal affective disorder and exces-
sive sweating [17, 33]. Under the guise of education,
companies define conditions and their associated symp-
toms in the minds of physicians and patients while
predicating the best available treatment [31].
The information provided in the disease awareness
campaigns collected in our study was often incom-
plete or misleading about the presentation of benefits
and harms of medicines and lacked balance. Preva-
lence rates were often inaccurate and suggested nearly
everyone had the health problem, such as a 90% cited
rate of neck and back pain (Table 2). Our results are
consistent with reports in other settings [34, 35] of
striking statistics, exaggerated stated incidence, preva-
lence or condition severity [36] [37]. They also mirror
existing evidence of the display of striking visuals [1]
and use of emotive messages to build brand loyalty
[20]. Inaccuracies and information imbalance can lead
to increased health care costs if new more expensive
drugs are used instead of equally effective lower-cost
drugs or non-drug treatments, and even to avoidable
injury or death if patients are encouraged to ask for
drugs that are less safe than alternatives [38]. For ser-
ious conditions, an additional concern is that patients
may seek less effective treatments, again leading to
avoidable harm.
We found many non-compliant websites in disease
awareness campaigns. Websites pose several challenges to
regulators, including difficulties ascertaining the source of
available information, frequently changing content, and
global access to websites that are covered by differing na-
tional regulations, including those originating in countries
Table 1 Frequency of information provided across materials and their Risk Ratio











versus news items (95% CI)
Suggestion to visit a physician 86 (91.5%) 132 (84.1%) 0.92 (0.883;1.01)
Key opinion leader or public figure quoted 89 (94.7%) 94 (59.9%) 0.63 (0.55;0.72)
Non-pharmaceutical interventions in addition to therapy 67 (71.3%) 86 (54.8%) 0.77 (0.63;0.93)
Referral to a website 4 (4.3%) 27 (17.2%) 4.04 (1.46;11.19)
Sponsorship by specific clinic 4 (4.3%) 22 (14.0%) 3.29 (1.17;9.26)
Mention of availability of a new medicine or treatment option 17 (18.1%) 16 (10.2%) 0.56 (0.30;1.06)
Pharmaceutical company name or logo 1 (1.1%) 13 (8.3%) 7.78 (1.03;58.55)
Patient organization or support group 4 (4.3%) 9 (5.7%) 1.35 (0.43;4.25)
Brand-name pharmaceutical product 5 (5.3%) 6 (3.8%) 0.72 (0.22;2.29)
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Table 2 Examples of non-compliance per key criteria from the disease awareness campaigns
Key criteria Problem identified Example (condition)
Promotional
information
Reference to pharmaceutical products to treat a condition or
disease in combination with:
- the name, logo and website of a pharmaceutical company;
- or a website for a disease awareness campaign;
- or quick response codes to dedicated websites.
“For example, one of the current treatments recommended by
doctors for premature ejaculation is a serotonin reuptake
inhibitor which prolongs intercourse for men older than 18 for
up to 200–400%”. The name and logo of a pharmaceutical
company as well as a dedicated website are mentioned.
(Premature ejaculation) [32]
“My doctor informed me about a compassionate use program in
which 17 patients with hepatitis C had an opportunity to receive
the new non-interferon therapy for free, which guaranteed 97–
100% cure rate. […] The program was supported by pharmaceut-
ical company X”. (Hepatitis C) [21]
A website about upper respiratory tract conditions states:
“inhaled corticosteroids are the most effective bronchial asthma
therapy”. The website includes the logo and the name of an
asthma medication manufacturer (Asthma, website, LV).
“Selective progesterone receptor modulator is the approved
pharmaceutical treatment for uterine fibroids. It reduces bleeding
and fibroid volume.” The website includes the logo of a
pharmaceutical company, as well as a section for specialists





No reference is provided to the sources of information
provided about prevalence of disease.
“Approximately 90% of the world population suffers from lower
back, neck line and muscle pain…” (Back pain, RU)
“Every 30 s someone has a fracture due to osteoporosis”.
(Osteoporosis, RU)
“After reaching 60 years of age, approximately 60% of population
suffers from venous insufficiency” (Varicose veins, LV)
“It is possible that you are among the 90% of the population
who suffer from herpes blisters. Here is the information that you
need to know about the herpes virus.” (Herpes, LV)
“Approximately half of ovarian cancer cases are lethal. This is due
to the asymptomatic nature of the cancer and delayed
diagnosis” (Cancer, LV)
Use of fear Reference to disability caused by the disease, either through
text or picture.
“If left untreated hemorrhoids will only get worse – inflamation
will develop into abcess, pain will increase, bleeding and
prolapse will form thrombs.” (Hemorrhoids, RU)
“If Lyme disease is not diagnosed and treated in a timely
manner, other symptoms of Lyme disease can develop several
weeks, months or years after the tick bite, such as arthritis,
nervous system or cardiovascular disorders” (Lyme disease, LV)
Inadequate
language
Uses medical terminology “[High blood pressure] also increases the risk of heart diseases -
ischemic heart disease, cardiomyopathy, development of
infarction and stroke.” (Cardiovascular disease, LV)
Lack of balance More emphasis on the benefits of pharmaceutical treatment
than risks. Symptoms are accentuated by layout and/or
enumeration. Risk factors are portrayed as diseases. Treatment
is accentuated.
“Botulin injections are one of the most effective methods to fight
excessive sweating. […] The effect will appear on the 4th to 6th
day after the injection and will last six to 9 months. ”(Excessive
sweating, LV).
Symptoms are referred to in headings in big and bold typeface.
(Diabetes, Nr 105, LV) (Asthma, Nr 30) (Alzheimer, Nr 138, LV)
“There are several tablets you can use for the treatment of
erectile dysfunction. […] There is a high chance that treatment
will work (in 8 cases out of 10 treatment is effective). Please
discuss the advantages and disadvantages of these treatments
with your doctor.” (Erectile dysfunction website, LV)
Use of
testimonials
Specialist mentions treatment and specific drug classes Quote from a general practitioner “If you have frequent and
pronounced herpes infections you will need to use acyclovir
[tablets] – a serious medication in high doses.” (Herpes simplex
infection, Nr. 9, LV)
A comparison is made of the patient’s experience before and “I trust my doctor a lot but I was still worried that [with a new
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where direct-to-consumer advertising of prescription
medicines is legal [5]. Nearly any user worldwide can en-
counter unregulated and unmonitored pharmaceutical in-
formation online [1].
Concerns have been raised about campaigns’ potential
to exaggerate the risks of a condition, which may result
in increased anxiety and unnecessary visits to doctors
[37]. When adoption of newer more expensive products
without established advantages over cheaper alternatives
is encouraged, this can lead to more doctor visits and in-
appropriate prescribing [17, 39, 40], shifting both the
quality and the costs of care [3]. This is particularly crit-
ical in Latvia with its under-resourced health system
[24]. Latvian public expenditure on health is remarkably
low when compared with neighbouring countries with
similar economic development, and out-of-pocket pay-
ments are amongst the highest in the European Union
[24]. This might explain why 14% (if not more) of the
disease awareness campaigns were sponsored by private
clinics. The commercial imperative behind these
campaigns may be fuelling otherwise unnecessary diag-
nostic testing and treatment. Such strategies do not
comply with the WHO Ethical Criteria which clearly
outlines that promotional activities should “not take un-
due advantage of people’s concern for their health” [22].
As the implementation of the WHO Ethical Criteria
remains incomplete across the world, researchers have
called for an update, claiming that many new marketing
strategies are not adequately covered by the 1988 docu-
ment [41]. One of the points highlighted by researchers
is the need to expand the document to include a broader
range of ethical values, providing also details on how to
interpret and act upon them. Our methodology offers
another approach, showing that the existing principles
can be interpreted and applied into a practical tool enab-
ling further scrutiny of promotional materials distin-
guishing legitimate awareness campaigns from covert
unbranded advertising.
We found several disease awareness campaigns that
referred directly to a specific brand-name drug or
Table 2 Examples of non-compliance per key criteria from the disease awareness campaigns (Continued)
Key criteria Problem identified Example (condition)
after treatment with a specific drug. therapy] I would experience the same side effects I had before...
This time everything was different! I only had to worry about
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indirectly to a treatment but which also included the
company’s name or logo, in contravention of the EU dir-
ective prohibiting direct-to-consumer advertising of
prescription-only medicines. The Latvian Health In-
spectorate reported that 15% of the contraventions to
advertising regulation in 2016 were direct-to-consumer
advertisements for prescription-only medicines [42].
However, despite this experience, the Inspectorate does
not actively monitor disease awareness campaigns. There
is a contradiction between prescription-only status, re-
quiring provision by clinicians with specialised training
and knowledge, and allowing those same drugs to be
marketed to people who lack that specialised knowledge
[43]. The overall lack of compliance with current inter-
national and European standards points to the need for
more active monitoring and enforcement. One strategy
at hand would be the development and implementation
of specific guidance on disease awareness campaigns and
communication on prescription-only medicines similarly
to what has happened in the United Kingdom and in the
Netherlands [23].
Our study had some limitations. As the study period
covered 6 months, seasonality is likely to have influenced
the content of campaigns. We would not expect an ef-
fect on quality, however. As one of our aims was to
probe the campaigns’ compliance with the guidelines, we
opted to include all types of campaigns. Not all were
necessarily sponsored by pharmaceutical companies.
One of the striking findings was that the name of the
sponsor was not included in 78% of the cases, thus
we were unable to clearly identify the subset which
was directly or indirectly supported by pharmaceutical
companies. Due to this limitation, we were also not
able to assess whether the sponsor had ratified or not
self-regulatory guidelines. Additionally, while we did
not use the instrument to assess news items, we
found some features consistent with drug promotion
in news coverage of specific conditions and new treat-
ments, such as use of key opinion leaders and lack of
information balance. Further application of the instru-
ment in other jurisdictions could shed light on the
enforcement status of disease awareness campaigns
and inform future policy about adequate measures to
respond to the challenges raised by this type of pro-
motional activities.
Conclusion
Disease awareness campaigns are present in Latvian printed
and online media. Their compliance with international and
European regulatory standards (namely EU law and
pharmaceutical industry self-regulatory guidelines) is low.
This raises concerns about the nature of information being
conveyed. Through lack of balance, missing sponsorship in-
formation, and misleading or incomplete information, these
campaigns could contribute to inaccurate self-diagnosis
and generate demand among those who might not need
medical treatment.
Fig. 2 Non-compliance of disease awareness campaigns per key criteria*. *See Additional file 2: Table S2 for operational definitions of the key criteria
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We have developed an instrument to systematically
evaluate the information content of disease awareness
campaigns. The use of this instrument may help identify
promotional campaigns and encourage the effective
monitoring and implementation of the regulations.
Additional files
Additional file 1: Table S1. Data collection. List of publications
included. (DOCX 16 kb)
Additional file 2: Table S2. Overlap between WHO Ethical Criteria,
Dutch Self-regulatory guidelines and the instrument. Table S2. Provides
an overlap between relevant provisions within the WHO Ethical Criteria
for Medicinal Drug Promotion and the Dutch Self-Regulatory (CGR)
Guidelines for provision of information on prescription medicines and the
relevant sections of the instrument. (DOCX 116 kb)
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